{"id":228194,"date":"2026-01-01T21:28:19","date_gmt":"2026-01-02T03:28:19","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2026\/01\/parkinson-disease-snca-risk-variants-are-associated-with-higher-asymmetric-putamen-dopaminergic-dysfunction"},"modified":"2026-01-01T21:28:19","modified_gmt":"2026-01-02T03:28:19","slug":"parkinson-disease-snca-risk-variants-are-associated-with-higher-asymmetric-putamen-dopaminergic-dysfunction","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2026\/01\/parkinson-disease-snca-risk-variants-are-associated-with-higher-asymmetric-putamen-dopaminergic-dysfunction","title":{"rendered":"Parkinson Disease SNCA Risk Variants Are Associated With Higher Asymmetric Putamen Dopaminergic Dysfunction"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/parkinson-disease-snca-risk-variants-are-associated-with-higher-asymmetric-putamen-dopaminergic-dysfunction2.jpg\"><\/a><\/p>\n<p>This study assessed the endophenotypic potential of striatal dopamine transporter uptake in carriers of Parkinson disease\u2013associated SNCA genetic risk variants.<\/p>\n<hr>\n<p>ObjectivesThe aim of this study was to investigate the endophenotypic potential of striatal dopamine transporter (DAT) uptake in carriers of Parkinson disease (PD)\u2013associated SNCA genetic risk variants. MethodsWe analyzed 381 patients with de novo PD from the Parkinson\u2019s Progression Markers Initiative (PPMI). The genotype of previously identified PD-related SNCA risk variants was extracted and used to compute an individual PD-specific SNCA genetic risk score (GRS). Striatal DAT uptake was quantified using <sup>123 <\/sup>I\u2010FP\u2010CIT SPECT and assessed at baseline and 24-month follow-up. Mixed models were applied to explore the relationship between striatal <sup>123 <\/sup>I\u2010FP\u2010CIT SPECT specific binding ratios (SBRs) and PD SNCA risk variants.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>This study assessed the endophenotypic potential of striatal dopamine transporter uptake in carriers of Parkinson disease\u2013associated SNCA genetic risk variants. ObjectivesThe aim of this study was to investigate the endophenotypic potential of striatal dopamine transporter (DAT) uptake in carriers of Parkinson disease (PD)\u2013associated SNCA genetic risk variants. MethodsWe analyzed 381 patients with de novo PD [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,412,47],"tags":[],"class_list":["post-228194","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-genetics","category-neuroscience"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/228194","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=228194"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/228194\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=228194"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=228194"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=228194"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}